InflaRx (IFRX) EPS (Basic) (2017 - 2026)

InflaRx (IFRX) posted EPS (Basic) of -$0.1 for Q1 2026, down 115.74% sequentially from $0.62 in Q4 2025, and up 34.44% YoY from -$0.07 in Q1 2025.

InflaRx (IFRX) EPS (Basic) (2017 - 2026) Analysis & Trends

InflaRx has reported EPS (Basic) for 10 years, with the latest figure at -$0.1 in Q1 2026.

Quarterly EPS (Basic) rose 34.44% year-over-year to -$0.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $0.07 (down 5.03% YoY) and the FY2025 annual result came in at -$0.77, up 8.89% from the prior year.
EPS (Basic) fell to -$0.1 in Q1 2026 per IFRX's latest filing, from $0.62 in the prior quarter.
Over five years, EPS (Basic) peaked at $0.8 in Q4 2024 and troughed at -$269109.1 in Q1 2023.
A 5-year average of -$15830.0 and a median of -$0.18 in 2022 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2023 and 2024: EPS (Basic) plunged 78645721.38% in 2023, then surged 431.22% in 2024.
Over 5 years, EPS (Basic) stood at $0.53 in 2022, then tumbled by 145.73% to -$0.24 in 2023, then soared by 431.22% to $0.8 in 2024, then fell by 22.29% to $0.62 in 2025, then plunged by 115.74% to -$0.1 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.1, $0.62, and -$0.21 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	12.62
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	7.59
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-1.96
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	2.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.23
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.06
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.18
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-0.72
10	InflaRx	135.25 Mn	-49.00 Mn	2.74 Bn	-0.11

Download Data